DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
DiaMedica Therapeutics (Nasdaq: DMAC) has appointed Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. O'Connor brings significant biopharmaceutical industry experience, most notably as CEO of Ambrx Biopharma, where he led the company from a $40 million valuation to a $2 billion acquisition by Johnson & Johnson in just 14 months.
DiaMedica is developing treatments for acute ischemic stroke (AIS) and preeclampsia (PE). AIS accounts for 87% of all strokes and is the leading cause of combined mortality and morbidity worldwide. PE affects 50,000 severe cases annually in the United States. O'Connor's expertise spans capital markets, licensing, business development, corporate strategy, clinical development, and regulatory compliance.
O'Connor is a former U.S. Marines Captain, holds a BA from Boston University and a JD from Penn State Dickinson Law, and has served on multiple public company boards and as Vice Chairman of BioNJ.
DiaMedica Therapeutics (Nasdaq: DMAC) ha nominato Daniel J. O'Connor nel suo Consiglio di Amministrazione, con effetto dal 20 febbraio 2025. O'Connor porta con sé una significativa esperienza nell'industria biofarmaceutica, in particolare come CEO di Ambrx Biopharma, dove ha guidato l'azienda da una valutazione di 40 milioni di dollari a un'acquisizione di 2 miliardi di dollari da parte di Johnson & Johnson in soli 14 mesi.
DiaMedica sta sviluppando trattamenti per l'ictus ischemico acuto (AIS) e la preeclampsia (PE). L'AIS rappresenta l'87% di tutti gli ictus ed è la principale causa di mortalità e morbidità combinata a livello mondiale. La PE colpisce annualmente 50.000 casi gravi negli Stati Uniti. L'esperienza di O'Connor spazia dai mercati dei capitali, alla concessione di licenze, allo sviluppo commerciale, alla strategia aziendale, allo sviluppo clinico e alla conformità normativa.
O'Connor è un ex Capitano dei Marines degli Stati Uniti, ha conseguito una laurea presso la Boston University e un JD presso la Penn State Dickinson Law, ed è stato membro di diversi consigli di amministrazione di aziende pubbliche e Vice Presidente di BioNJ.
DiaMedica Therapeutics (Nasdaq: DMAC) ha nombrado a Daniel J. O'Connor en su Junta Directiva, con efecto a partir del 20 de febrero de 2025. O'Connor aporta una experiencia significativa en la industria biofarmacéutica, especialmente como CEO de Ambrx Biopharma, donde llevó a la compañía de una valoración de 40 millones de dólares a una adquisición de 2 mil millones de dólares por parte de Johnson & Johnson en solo 14 meses.
DiaMedica está desarrollando tratamientos para el accidente cerebrovascular isquémico agudo (AIS) y la preeclampsia (PE). El AIS representa el 87% de todos los accidentes cerebrovasculares y es la principal causa de mortalidad y morbilidad combinada en todo el mundo. La PE afecta anualmente a 50,000 casos severos en los Estados Unidos. La experiencia de O'Connor abarca mercados de capitales, licencias, desarrollo empresarial, estrategia corporativa, desarrollo clínico y cumplimiento regulatorio.
O'Connor es un ex Capitán de los Marines de EE. UU., tiene una licenciatura de la Boston University y un JD de la Penn State Dickinson Law, y ha servido en múltiples juntas de empresas públicas y como Vicepresidente de BioNJ.
DiaMedica Therapeutics (Nasdaq: DMAC)는 2025년 2월 20일부터 Daniel J. O'Connor를 이사회에 임명했습니다. O'Connor는 Ambrx Biopharma의 CEO로서 4천만 달러의 가치를 가진 회사를 단 14개월 만에 존슨앤존슨에 20억 달러에 인수시키는 등 생명공학 산업에서 상당한 경험을 쌓았습니다.
DiaMedica는 급성 허혈성 뇌졸중(AIS)과 자간전증(PE)에 대한 치료제를 개발하고 있습니다. AIS는 모든 뇌졸중의 87%를 차지하며, 전 세계적으로 합병증과 사망의 주요 원인입니다. PE는 미국에서 매년 50,000건의 중증 사례에 영향을 미칩니다. O'Connor의 전문 분야는 자본 시장, 라이센스, 사업 개발, 기업 전략, 임상 개발 및 규제 준수를 포함합니다.
O'Connor는 전 미국 해병대 대위이며, 보스턴 대학교에서 학사 학위를, 펜주립 대학교 디킨슨 법대에서 JD를 취득했으며, 여러 상장 기업의 이사회에서 활동했으며 BioNJ의 부회장을 역임했습니다.
DiaMedica Therapeutics (Nasdaq: DMAC) a nommé Daniel J. O'Connor à son Conseil d'Administration, à compter du 20 février 2025. O'Connor apporte une expérience significative dans l'industrie biopharmaceutique, notamment en tant que PDG de Ambrx Biopharma, où il a dirigé l'entreprise d'une valorisation de 40 millions de dollars à une acquisition de 2 milliards de dollars par Johnson & Johnson en seulement 14 mois.
DiaMedica développe des traitements pour l'accident vasculaire cérébral ischémique aigu (AIS) et la prééclampsie (PE). L'AIS représente 87 % de tous les AVC et est la principale cause de mortalité et de morbidité combinées dans le monde. La PE affecte 50 000 cas graves chaque année aux États-Unis. L'expertise d'O'Connor couvre les marchés de capitaux, la licence, le développement commercial, la stratégie d'entreprise, le développement clinique et la conformité réglementaire.
O'Connor est un ancien capitaine des Marines américains, titulaire d'une licence de la Boston University et d'un JD de la Penn State Dickinson Law, et a siégé à plusieurs conseils d'administration d'entreprises publiques ainsi qu'en tant que vice-président de BioNJ.
DiaMedica Therapeutics (Nasdaq: DMAC) hat Daniel J. O'Connor mit Wirkung zum 20. Februar 2025 in seinen Vorstand berufen. O'Connor bringt umfassende Erfahrung in der biopharmazeutischen Industrie mit, insbesondere als CEO von Ambrx Biopharma, wo er das Unternehmen innerhalb von nur 14 Monaten von einer Bewertung von 40 Millionen Dollar zu einer Übernahme durch Johnson & Johnson im Wert von 2 Milliarden Dollar führte.
DiaMedica entwickelt Behandlungen für akuten ischämischen Schlaganfall (AIS) und Präeklampsie (PE). AIS macht 87 % aller Schlaganfälle aus und ist die häufigste Ursache für kombinierte Sterblichkeit und Morbidität weltweit. PE betrifft jährlich 50.000 schwere Fälle in den Vereinigten Staaten. O'Connors Expertise umfasst Kapitalmärkte, Lizenzierung, Geschäftsentwicklung, Unternehmensstrategie, klinische Entwicklung und regulatorische Compliance.
O'Connor ist ein ehemaliger Kapitän der US-Marines, hat einen BA von der Boston University und einen JD von der Penn State Dickinson Law und hat in mehreren Vorständen öffentlicher Unternehmen sowie als Vizepräsident von BioNJ gedient.
- Appointment of experienced executive with proven track record of value creation (led Ambrx from $40M to $2B acquisition)
- Addition of strategic expertise in capital markets, licensing, and business development
- Enhanced board oversight in clinical development and regulatory compliance
- None.
Mr. O’Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O’Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, where under his leadership the company grew from a
“DiaMedica’s progress over the past twelve months is highly impressive and attributable to its efforts to provide new treatment options for acute ischemic stroke (AIS) and preeclampsia (PE), both areas of high unmet medical need,” stated Mr. O’Connor. “AIS is the leading cause of combined mortality and morbidity worldwide, and
Beyond his executive leadership, Mr. O’Connor has served on the boards of multiple public companies and non-profit entities. Mr. O’Connor has leveraged his experience to guide and support life science companies, serving on the Board of Trustees of BioNJ for several years, including several years as its Vice Chairman. He has received several awards, including being named the Ernst & Young Entrepreneur of the Year® in
“We are thrilled to welcome Dan to our Board,” said Rick Pauls, President and Chief Executive Officer of DiaMedica. “His extensive experience leading biotech companies through critical growth phases, combined with his deep understanding of corporate governance and strategic development, will be invaluable as we continue advancing our pipeline and executing our mission to bring transformative therapies to patients.”
About DM199
DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for acute ischemic stroke and preeclampsia. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the case of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibition of apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis. In preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224751069/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
When will Daniel O'Connor join DiaMedica Therapeutics (DMAC) Board of Directors?
What was Daniel O'Connor's most recent achievement in the biotech industry before joining DMAC?
What are the main therapeutic areas DiaMedica (DMAC) is focusing on?
How many severe cases of preeclampsia occur annually in the United States according to DMAC?
What percentage of all strokes are ischemic according to DMAC's data?
